This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ariad Sarcoma Drug Delays Progression

CAMBRIDGE, Mass. ( TheStreet) --An oral cancer drug from Ariad Pharmaceuticals (ARIA - Get Report) helped patients with soft tissue and bone cancer remain in remission longer than a placebo, according to results from a phase III study released Tuesday.

The Ariad drug, ridaforolimus, is being jointly developed by Merck (MRK - Get Report), which plans to file for approval later this year based on positive data from Tuesday's study.

The "Succeed" study enrolled 711 patients with soft-tissue or bone sarcoma who responded to previous treatment with chemotherapy. Patients were then treated with daily ridaforolimus or a placebo to determine whether the former could extend the time before the patients' tumors started to grow again.

Based on a full, independent analysis of the study, patients treated with ridaforolimus reported a 28% reduction in risk of cancer progression compared to patients treated with a placebo. The result was highly statistically significant, achieving the primary endpoint of the study.

At the median, ridaforolimus' benefit was more modest, demonstrating a 3.1-week benefit in progression-free survival over placebo (17.7 weeks compared to 14.6 weeks.)

The most common side effects of ridaforolimus observed in the study stomatitis (mouth sores), fatigue, diarrhea and thrombocytopenia.

Patients in the study are still be followed to determine, in part, whether ridaforolimus can help sarcoma patients live longer. The study was conducted under a Special Protocol Agreement with FDA that allows the company to seek approval based on the positive disease-progression endpoint.

Ariad shares were up 36% to $7.16 in pre-market trading.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARIA $7.22 0.70%
MRK $54.70 -1.90%
AAPL $93.49 -1.40%
FB $116.25 -0.41%
GOOG $691.72 0.10%


Chart of I:DJI
DOW 17,701.94 -128.82 -0.72%
S&P 500 2,055.32 -20.49 -0.99%
NASDAQ 4,751.4360 -53.8550 -1.12%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs